Five-year, multicenter safety study of fixed-combination latanoprost/timolol (Xalacom) for open-angle glaucoma and ocular hypertension

Journal of Glaucoma

Volumn 20, Issue 4, 2011, Pages 215-222

  Alm, Albert ^a   Grunden, John W ^b   Kwok, Kenneth K ^b  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b PFIZER INC   (United States)

Author keywords

adverse events; fixed combination latanoprost timolol; iris pigmentation; long term safety

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; LATANOPROST PLUS TIMOLOL;

AGED; ARTICLE; BRADYCARDIA; CATARACT; CONJUNCTIVITIS; CORNEA EROSION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; EYE ALLERGY; EYE IRRITATION; EYE PHOTOGRAPHY; EYELASH; FEMALE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; INTRAOCULAR HYPERTENSION; IRIDOCYCLITIS; IRIS PIGMENTATION; IRITIS; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; OPEN ANGLE GLAUCOMA; OPTIC NERVE ATROPHY; PERIORBITAL SKIN; PHASE 3 CLINICAL TRIAL; PIGMENTATION; PRIORITY JOURNAL; PUNCTATE KERATITIS; RETINA MACULA EDEMA; RETINA NEOVASCULARIZATION; RETINA VEIN OCCLUSION; SIDE EFFECT; SKIN; SYNCOPE; UNILATERAL BLINDNESS; UVEITIS;

AGED; ANTIHYPERTENSIVE AGENTS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; EYE COLOR; EYELASHES; FEMALE; GLAUCOMA, OPEN-ANGLE; HAIR COLOR; HAIR DISEASES; HUMANS; HYPERPIGMENTATION; INTRAOCULAR PRESSURE; IRIS DISEASES; MALE; OCULAR HYPERTENSION; PROSTAGLANDINS F, SYNTHETIC; TIMOLOL; TONOMETRY, OCULAR;

EID: 79955161443     PISSN: 10570829     EISSN: None     Source Type: Journal    
DOI: 10.1097/IJG.0b013e3181e08121     Document Type: Article

References (29)

1. Diestelhorst M, Larsson LI; for the European-Canadian Latanoprost Fixed Combination Study Group. A 12-week, randomized, double-masked, multicenter study of the fixed combination of latanoprost and timolol in the evening versus the individual components. Ophthalmology. 2006;113:70-76. (Pubitemid 43021730)
2. Garcia-Sanchez J, Rouland JF, Spiegel D, et al. A comparison of the fixed combination of latanoprost and timolol with the unfixed combination of brimonidine and timolol in patients with elevated intraocular pressure. A six month, evaluator masked, multicentre study in Europe. Br J Ophthalmol. 2004; 88:877-883. (Pubitemid 38869546)
3. Higginbotham EJ, Feldman R, Stiles M, et al. Latanoprost and timolol combination therapy versus monotherapy: one-year randomized trial. Arch Ophthalmol. 2002;120:915-922. (Pubitemid 34755544)
4. Pfeiffer N; for the European Latanoprost Fixed Combination Study Group. A comparison of the fixed combination of latanoprost and timolol with its individual components. Graefes Arch Clin Exp Ophthalmol. 2002;240:893-899. (Pubitemid 36097111)
5. Shin DH, Feldman RM, Sheu WP, et al. Efficacy and safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure. Ophthalmology. 2004;111:276-282. (Pubitemid 38183227)
6. Stewart WC, Stewart JA, Day D, et al. Efficacy and safety of timolol maleate/latanoprost fixed combination versus timolol maleate and brimonidine given twice daily. Acta Ophthalmol Scand. 2003;81:242-246. (Pubitemid 36806261)
7. Lass JH, Eriksson GL, Osterling L, et al. Comparison of the corneal effects of latanoprost, fixed combination latanoprost-timolol, and timolol: a double-masked, randomized, one-year study. Ophthalmology. 2001;108:264-271. (Pubitemid 32115954)
8. Alm A, Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology. 1995;102:1743-1752. (Pubitemid 26004426)
9. Camras CB; for the United States Latanoprost Study Group. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. Ophthalmology. 1996;103:138-147. (Pubitemid 26046170)
10. Watson P, Stjernschantz J; for the Latanoprost Study Group. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. Ophthalmology. 1996;103:126-137. (Pubitemid 26046169)
11. Hollo G. The side effects of the prostaglandin analogues. Expert Opin Drug Saf. 2007;6:45-52. (Pubitemid 46150523)
12. Johnstone MA. Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am J Ophthalmol. 1997;124:544-547. (Pubitemid 27425878)
13. Wand M. Latanoprost and hyperpigmentation of eyelashes. Arch Ophthalmol. 1997;115:1206-1208. (Pubitemid 27387964)
14. Kook MS, Lee K. Increased eyelid pigmentation associated with use of latanoprost. Am J Ophthalmol. 2000;129:804-806. (Pubitemid 30604165)
15. Sharpe ED, Reynolds AC, Skuta GL, et al. The clinical impact and incidence of periocular pigmentation associated with either latanoprost or bimatoprost therapy. Curr Eye Res. 2007;32: 1037-1043. (Pubitemid 351412296)
16. Feldman RM. An evaluation of the fixed-combination of latanoprost and timolol for use in open-angle glaucoma and ocular hypertension. Expert Opin Pharmacother. 2004;5: 909-921. (Pubitemid 38489513)
17. Alm A, Schoenfelder J, McDermott J. A 5-year, multicenter, open-label, safety study of adjunctive latanoprost therapy for glaucoma. Arch Ophthalmol. 2004;122:957-965. (Pubitemid 39037958)
18. Goldberg I, Li XY, Selaru P, et al. A 5-year, randomized, open-label safety study of latanoprost and usual care in patients with open-angle glaucoma or ocular hypertension. Eur J Ophthalmol. 2008;18:408-416.
19. Warwar RE, Bullock JD, Ballal D. Cystoid macular edema and anterior uveitis associated with latanoprost use. Experience and incidence in a retrospective review of 94 patients. Ophthalmology. 1998;105:263-268. (Pubitemid 28090830)
20. Fechtner RD, Khouri AS, Zimmerman TJ, et al. Anterior uveitis associated with latanoprost. Am J Ophthalmol. 1998; 126:37-41. (Pubitemid 28341216)
21. Schumer RA, Camras CB, Mandahl AK. Putative side effects of prostaglandin analogs. Surv Ophthalmol. 2002;47(suppl 1): S219-S230. (Pubitemid 35232235)
22. Altintaş O, Yüksel N, Karabaş VL, et al. Cystoid macular edema associated with latanoprost after uncomplicated cataract surgery. Eur J Ophthalmol. 2005;15:158-161. (Pubitemid 40462749)
23. Ayyala RS, Cruz DA, Margo CE, et al. Cystoid macular edema associated with latanoprost in aphakic and pseudo-phakic eyes. Am J Ophthalmol. 1998;126:602-604. (Pubitemid 28475931)
24. Moroi SE, Gottfredsdottir MS, Schteingart MT, et al. Cystoid macular edema associated with latanoprost therapy in a case series of patients with glaucoma and ocular hypertension. Ophthalmology. 1999;106:1024-1029. (Pubitemid 30191566)
25. Alm A, Widengård I. Latanoprost: experience of 2-year treatment in Scandinavia. Acta Ophthalmol Scand. 2000;78:71-76. (Pubitemid 30095316)
26. Watson PG; for the Latanoprost Study Group. Latanoprost. Two years' experience of its use in the United Kingdom. Ophthalmology. 1998;105:82-87. (Pubitemid 28070605)
27. Wistrand PJ, Stjernschantz J, Olsson K. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color. Surv Ophthalmol. 1997;41(suppl 2): S129-S138. (Pubitemid 27154537)
28. Grierson I, Cracknell KP, Pfeiffer N. The iris after prostanoid treatment. Curr Opin Ophthalmol. 2001;12:112-118. (Pubitemid 32232082)
29. Albert DM, Gangnon RE, Grossniklaus HE, et al. A study of histopathological features of latanoprost-treated irides with or without darkening compared with non-latanoprost-treated irides. Arch Ophthalmol. 2008;126:626-631. (Pubitemid 351679556)